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Abstract While interferons (IFNs) (K, L and Q), a family of
cytokines, have the ability to exert the growth-inhibitory effect
on target cells, the molecular mechanism(s) by which IFNs
inhibit cell growth remains to be identified. Because IFN-
inducible ‘effector’ proteins mediate the biological activities of
IFNs, characterization of IFN-inducible proteins is critical to
identify their functional role in IFN action. One family (the 200-
family) of IFN-inducible proteins is encoded by structurally
related murine (Ifi202a, Ifi202b, Ifi203, Ifi204 and D3) and
human (IFI16, MNDA and AIM2) genes. The proteins encoded
by genes in the family share a unique repeat of 200-amino acids
and are primarily nuclear. The AIM2 gene is a newly identified
gene that is not expressed in a human melanoma cell line. Here
we report that AIM2 is estimated to be a 39 kDa protein and,
unlike other proteins in the family, is localized primarily in the
cytoplasm. Interestingly, overexpression of AIM2 in transfected
cells retards proliferation and, under reduced serum conditions,
increases the susceptibility to cell death. Moreover, AIM2 can
heterodimerize with p202 in vitro. Together, these observations
provide support to the idea that AIM2 may be an important
mediator of IFN action.
z 2000 Federation of European Biochemical Societies.
Key words: Interferon; 200-Protein family; AIM2;
Cell growth
1. Introduction
Interferons (IFNs) (K, L and Q) are a family of cytokines
with the ability to exert the growth-inhibitory e¡ect on target
cells [1,2]. While the IFNs are being used in the clinic to treat
various human diseases, including cancers, the molecular
mechanisms by which IFNs exert the growth-inhibitory e¡ect
remain to be identi¢ed. Because IFN-inducible ‘e¡ector’ pro-
teins mediate the biological activities of the IFNs [1], the
identi¢cation of the functional role(s) of IFN-inducible pro-
teins in IFN action is likely to improve our ability to use IFNs
e¡ectively.
One family of IFN-inducible proteins (the 200-family pro-
teins) includes p202a (previously p202), p202b, p203, p204
and D3 [3^6]. These proteins are encoded by six or more
structurally related murine genes, which form a tight cluster
(the 200-gene cluster) in the q21^q23 region of chromosome 1
[7,8]. The family also includes three highly homologous hu-
man proteins: IFI 16, myeloid nuclear di¡erentiation antigen
(MNDA) and AIM2 (Absent In Melanoma) [3,6]. The pro-
teins in this family share a unique repeat of 200-amino acids.
While p202, p204 and IFI 16 proteins contain two repeats of
200-amino acids (one a-type and one b-type), other proteins in
the family, including AIM2, contain only one repeat (a-type
or b-type). Additionally, a short sequence (MFHATVAT),
which is found in 200-amino acid repeats of some 200-family
proteins (for example, two repeats of p202 and a-type repeat
of AIM2), was found to be su⁄cient for homo- and hetero-
dimerization of the proteins in vitro [9]. While p203, p204, IFI
16 and MNDA proteins have a consensus sequence for nu-
clear localization and are primarily nuclear [3,6], p202 does
not have a consensus sequence for nuclear localization and is
detected both in the cytoplasm and nucleus [10].
The AIM2 gene was identi¢ed as one of several genes not
expressed in a human tumorigenic melanoma cell line, but was
expressed upon introduction of a normal chromosome 6, thus
resulting in the suppression of the malignant phenotype
[11,12]. Interestingly, the steady-state levels of the AIM2
RNA increase in HL-60 cell line after IFN-Q treatment [12],
raising the possibility that the IFN-induced levels of AIM2
protein may have a role in IFN action. The isolation and
sequencing of the AIM2 cDNA revealed that it contains an
open reading frame of 1032 bp corresponding to a putative
polypeptide of 344 amino acids with a predicted molecular
weight of 39.4 kDa [12]. Additionally, AIM2 protein contains
only one repeat (a-type) of 200-amino acids and shares strong
sequence similarity with 200-family proteins (for example, IFI
16, MNDA and p204) [6,12]. However, AIM2 protein remains
to be characterized with respect to its biochemical and bio-
logical functions.
To identify the possible functional role of AIM2 in IFN
action, we have characterized the AIM2 protein. Here we
report that AIM2 is estimated to be a 39 kDa protein. In
transfected cells, AIM2 protein is primarily localized in the
cytoplasm. Interestingly, the ectopic expression of AIM2 in
murine ¢broblasts retards cell proliferation. Additionally,
overexpression of AIM2 in murine ¢broblasts, under reduced
serum conditions, increased the susceptibility to cell death.
Furthermore, AIM2 binds to the full-length p202, but not
to a deletion mutant of p202 lacking the heterodimerization
motif, in vitro. Together, these observations provide support
to the idea that AIM2 may exert the growth-inhibitory e¡ect
of IFN.
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2. Materials and methods
2.1. Cell lines
The AKR-2B (originally a gift from Dr. H.L. Moses, Vanderbilt
University, Nashville, USA) was grown in Dulbecco’s modi¢ed Eagle
medium (with high glucose) supplemented with 10% fetal bovine se-
rum (FBS) in a 37‡C incubator with 5% CO2. If so indicated, cells
were incubated in growth medium supplemented with 0.1% FBS for
the indicated time.
2.2. Plasmids and generation of stable cell lines
To express AIM2 protein (tagged with V5 and 6UHis epitopes
towards the C-terminus of AIM2) in vitro or in transfected cells,
plasmid pcDNA3.1/AIM2 was used. The addition of two epitope
tags to AIM2 protein that is expressed from the above plasmid results
in addition of 33 amino acid residues. Murine AKR-2B cells were
transfected with plasmid pcDNA3.1/AIM2 or, as a control, with equal
amounts of empty vector (pcDNA3.1). The transfected cells were
selected in Zeocin (200 Wg per ml) for Zeocin-resistance. After 2 weeks,
Zeocin-resistance colonies (s 300) were pooled and the cultures were
maintained in 100 Wg per ml of Zeocin. For experiments, cells were
cultured without Zeocin.
2.3. In vitro transcription and translation
The RNA encoding AIM2 protein was transcribed in vitro (from
plasmid pcDNA3.1/AIM2) using T7 RNA polymerase and translated
in rabbit reticulocyte lysate either supplemented with [35S]methionine
or cold methionine as described previously [13]. To detect radiola-
beled AIM2 in rabbit reticulocyte lysates, the lysates were subjected
to SDS^PAGE followed by £uorography. The unlabeled AIM2 was
detected by immunoblotting using monoclonal anti-V5 epitope anti-
body (purchased from Invitrogen Corp., Carlsbad, CA, USA).
2.4. Cell cycle analyses
To determine cell cycle distribution, cells (1U106) were washed with
phosphate-bu¡ered saline (PBS), ¢xed with 70% ethanol and stored at
320‡C. For staining, the ¢xed cells were washed with PBS and in-
cubated for 5 min at room temperature in bu¡er containing 0.2%
Triton X-100, 1 mM EDTA in PBS. The cells were stained for 1 h
at room temperature with bu¡er containing 50 Wg per ml propidium
iodide and 50 Wg per ml of RNase. The samples were subjected to £ow
cytometry (FACStar PLUS, Becton and Dickinson) and analyzed us-
ing ModFit LT version 2.0 software (Variety Software House, Top-
sham, ME, USA).
2.5. Immunodetection of AIM2
To detect AIM2 levels by immunoblotting, transfected AKR-2B
cells were collected from plates in PBS and resuspended in modi¢ed
RIPA lysis bu¡er (50 mM Tris^HCl, pH 8.0, 250 mM NaCl, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with pro-
tease inhibitors (leupeptin, 50 Wg per ml; pepstatin A, 50 Wg per
ml; PMSF, 1 mM), and incubated at 4‡C for 30 min. Lysates were
sonicated brie£y before centrifugation at 14 000 rpm in a microfuge
for 10 min. Supernatants were collected and equal amounts of pro-
teins were processed for immunoblotting as described previously [10].
The monoclonal anti-V5 epitope antibody conjugated to horseradish
peroxidase (HRP) and monoclonal anti-His epitope antibody conju-
gated to HRP were purchased from Invitrogen Corp. (Carlsbad, CA,
USA) and used at 1:5000 dilution.
To test if AIM2 is phosphorylated in vivo, AIM2 was immunopre-
cipitated using anti-V5 or anti-His epitope antibodies from lysates
prepared from AKR-2B cells transfected with AIM2 expression plas-
mid. The immunoprecipitated proteins were immunodetected by a
mixture (1:1) of biotinylated phosphoserine and phosphothreonine-
speci¢c monoclonal antibodies.
2.6. Binding of AIM2 to glutathione-Sepharose beads loaded with GST
fusion proteins
Aliquots (10 Wl) from the reaction mixtures in which 35S-labeled
AIM2 protein had been translated in vitro were incubated with
washed glutathione-Sepharose beads (loaded with the indicated GST
fusion protein) in binding bu¡er (50 mM HEPES, 150 mM NaCl and
1% NP-40) at room temperature for 30 min. The beads were washed
¢ve times in binding bu¡er and the bound proteins were released by
boiling in protein sample bu¡er and subjected to SDS^PAGE fol-
lowed by £uorography.
3. Results and discussion
3.1. AIM2 is estimated to be a 39 kDa protein
As predicted from its sequence [12], the full-length AIM2
protein, when translated in a rabbit reticulocyte lysate from a
transcript transcribed in vitro, migrated between 47.5 and 32.5
kDa size protein markers (Fig. 1, lanes 2 and 6) (it is of note
that large amounts of protein in rabbit reticulocyte lysate
made it di⁄cult to estimate the size of AIM2 protein). While
the origin of two additional protein bands seen in lanes 2 and
Fig. 1. AIM2 is a 39 kDa protein. AIM2 protein was translated (from a transcript generated in vitro) in rabbit reticulocyte lysate supplemented
with either [35S]methionine (lanes 1, 2, 4 and 5) or cold methionine (lanes 3 and 6). The translation reaction mixtures without any transcripts
added (lanes 1 and 4) or after addition of the AIM2 transcript (lanes 2, 3, 5 and 6) were analyzed by SDS^PAGE followed by either £uorogra-
phy (lanes 1^3) or immunoblotting using monoclonal anti-V5 epitope antibodies. The full-length AIM2 protein band is indicated by an arrow.
Total cell extracts prepared from murine AKR-2B cell lines stably transfected with the empty vector (lane 2) or AIM2 expression plasmid (lane
1) were analyzed for the expression of AIM2 by SDS^PAGE followed by immunoblotting using monoclonal anti-V5 epitope antibodies. The
full-length AIM2 protein band is indicated by an arrow.
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6 (Fig. 1a) remains to be established, it is possible that these
two fast migrating protein bands correspond to the transla-
tion products whose translation is initiated at the internal
initiator codons in AIM2 RNA. Consistent with this predic-
tion, we ¢nd that the AIM2 cDNA sequence contains two
potential internal translational initiation sites to initiate the
translation of AIM2 protein (which could give rise to two
additional translation products of the sizes seen in lanes 2
and 6).
Because in vivo posttranslational modi¢cations of proteins
can contribute to the molecular weight, we determined the size
of AIM2 protein that was expressed in mammalian cells. As
shown in Fig. 1b (lane 1), AIM2 protein in extracts prepared
from transfected cells migrated as approximately 39 kDa pro-
tein, providing support to the idea that in vivo posttransla-
tional modi¢cations do not apparently contribute to a signi¢-
cant change in the mobility of the AIM2 protein.
Because the amino acid sequence of AIM2 contains a po-
tential consensus sequence for phosphorylation by several
protein kinases [12], we tested if AIM2 is phosphorylated in
vivo. In cycling AKR-2B cells, we could not detect phosphor-
ylation of Ser and Thr residues in AIM2. Further work will be
needed to determine if AIM2 is phosphorylated on tyrosine
residues.
3.2. Cytoplasmic localization of AIM2
The analyses of the AIM2 amino acid sequence by the
PSORT II program [14], to predict the subcellular location,
revealed that AIM2 is predicted to be primarily localized in
the cytoplasm and not in the nucleus. Additionally, it is pre-
dicted to localize in the cytoplasmic membranous organelles,
including mitochondria. Therefore, we chose to test if AIM2
is a cytoplasmic protein. To determine the subcellular location
of AIM2, we stably overexpressed AIM2 in murine AKR-2B
cells and performed cell fractionation into the cytoplasmic
and nuclear fraction. As shown in Fig. 2a, AIM2 was detected
only in the cytoplasmic fraction and not in the nuclear frac-
tion. To con¢rm this observation, we transfected AIM2 en-
coding plasmid into murine AKR-2B cells and stained the
transfected cells with anti-V5 antibodies. As shown in Fig.
2b, AIM2, when overexpressed in transfected cells, is primar-
ily localized in the cytoplasm. Together, these observations
indicate that AIM2 is the ¢rst protein in the 200-family pro-
teins to be localized primarily in the cytoplasm. Based on its
cytoplasmic localization, it is conceivable that AIM2 may
have functions di¡erent than the other members of the family.
3.3. Overexpression of AIM2 inhibits cell growth
Because 200-family proteins, including p202, participate in
Fig. 2. In transfected cells, AIM2 is primarily localized in the cytoplasm. (a) Murine AKR-2B cells stably transfected with AIM2 expression
plasmid were fractionated into the cytoplasmic (lane 1) and nuclear fraction (lane 2). The fractions containing equal amounts of protein were
analyzed by SDS^PAGE followed by immunoblotting using monoclonal anti-V5 epitope antibodies. The AIM2 protein band is indicated by an
arrow. (b) Murine AKR-2B cells were transiently transfected with AIM2 expression plasmid and the transfected cells were immunostained using
monoclonal anti-V5 epitope antibodies conjugated to HRP. The cytoplasmic location of AIM2 is indicated by a white arrow.
Table 1
Constitutive overexpression of AIM2 in AKR-2B cells and cell cycle
distribution
G0/G1 S G2/M
Control Exp. 1 27.0 63.6 9.3
Control Exp. 2 37.1 47.5 15.3
AIM2 Exp. 1 35.8 54.2 9.9
AIM2 Exp. 2 35.6 51.2 13.1
AKR-2B cells, stably transfected with pCDNA3.1 (control) or
pCDNA3.1/AIM2 (AIM2) plasmid, were subjected to £ow cytomet-
ry as described in Section 2. The percentages of cells in a particular
phase of the cell cycle were determined for each sample (in dupli-
cates) in two experiments and an arithmetic mean of two readings
is shown for each experiment.
Fig. 3. Overexpression of AIM2 protein retards proliferation of
murine AKR-2B ¢broblasts. Cells stably transfected with the empty
vector (black squares) or AIM2 expression plasmid (white squares)
were seeded in a six well plate (in duplicates) in growth medium
and cells were harvested at the indicated time to count cells. Each
sample was counted three times. The standard error bars are indi-
cated.
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the regulation of cell proliferation [6,15,16], we tested if ex-
pression of AIM2 a¡ects cell proliferation. For this purpose,
murine AKR-2B cells (we chose these cells because in these
cells the ectopic expression of p202, a 200-family protein, was
found to inhibit cell growth) [15,16] were either transfected
with a plasmid (pCDNA3.1/AIM2) encoding AIM2 or, as a
control, empty vector (pCDNA3.1). The transfected cells were
selected for Zeocin-resistance. Interestingly, transfection of
AIM2 encoding plasmid did not result in a signi¢cant de-
crease in colony formation as compared to cells transfected
with the empty vector (control cells) (376 colonies versus 400
colonies, respectively). However, we found that cells which
Fig. 4. AIM2 translated in vitro binds to GST^p202 fusion protein. (a) Binding of AIM2 to GST^p202. A⁄nity chromatography. In vitro-
translated labeled AIM2 was incubated with glutathione-Sepharose beads loaded with GST (lane 2), GST^p202(295^445) (lane 3) or GST^
p202(19^445) (lane 4). The bound proteins were analyzed by SDS^PAGE followed by £uorography. As a control, an aliquot (2 Wl) of transla-
tion reaction mixture was loaded in lane 1. The full-length AIM2 protein band is indicated by an arrow. (b) Schematic representation of p202,
its segments and their abilities to bind to AIM2 in a⁄nity chromatography. The thin vertical lines indicate the borders of the 200-amino acid
repeat regions a and b. The inserts indicate the positions of the conserved sequence MFHATVAT. The numbers of the N- and C-terminal ami-
noacyl residues of these sequences are indicated. +, binding; 3, no detectable binding.
Fig. 5. Overexpression of AIM2 in murine AKR-2B cells increases the susceptibility to cell death under reduced serum conditions. Cells stably
transfected with vector (control cells) or AIM2 expression plasmid (AIM2) were incubated in growth medium supplemented with either 10% or
0.1% FBS for 2 days. After 2 days, cells were photographed for alterations in their morphology and a decrease in cell number.
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overexpressed AIM2 exhibited a decreased growth rate as
compared to the control cells (Fig. 3). These cells did not
appear to accumulate in a particular phase of the cell cycle
in two independent experiments (see Table 1). This observa-
tion is consistent with our previous observation in which we
found that overexpression of p202 also decreased the cell
growth rate without accumulation of cells in a particular
phase of the cell cycle [16].
While it has been reported that the growth suppression by
the 200-family proteins requires the presence of at least two
200-amino acid repeats (AIM2 has only one repeat) [17], it is
interesting that overexpression of AIM2 in AKR-2B cells slows
cell proliferation. Although it remains to be seen how AIM2
regulates cell growth, our observations raise an interesting pos-
sibility that the 200-family proteins with only one repeat of
200-amino acids can also negatively regulate cell growth.
3.4. AIM2 can heterodimerize with p202
Because the 200-amino acid repeat in AIM2 protein con-
tains the conserved sequence MFHATVAT, which is su⁄cient
for heterodimerization of p202 with other proteins in the fam-
ily [9], we hypothesized that AIM2 regulates cell growth by
binding to other proteins in the family. Therefore, we tested if
AIM2 can bind to p202. As shown in Fig. 4, the full-length
p202, but not the N-terminal truncated p202, which lacks the
dimerization motif (MFHATVAT) in p202, selectively bound
to in vitro-translated AIM2. This observation is consistent
with the possibility that binding of AIM2 to p202 depends
on the presence of the sequence MFHATVAT. It is of note
that substitution of the His residue in the sequence MFHAT-
VAT by Phe in p202 repeats abrogates the ability of p202 to
interact with 53BP protein and inhibit cell growth [18]. While
the signi¢cance of binding of AIM2 to p202 remains to be
explored, this observation raises the possibility that AIM2
functionally interacts with p202 and other proteins to exert
the growth regulatory e¡ects of IFN.
3.5. Overexpression of AIM2, under reduced serum conditions,
increases the susceptibility to cell death
Because decreased levels of p202, under reduced serum con-
ditions, were found to increase the susceptibility of AKR-2B
cells to cell death by apoptosis [19], we tested if overexpres-
sion of AIM2 (which can bind to p202 in vitro) has any a¡ect
on cell death. As shown in Fig. 5, overexpression of AIM2 in
AKR-2B cells, under reduced serum conditions, increased the
susceptibility to cell death. While it remains to be seen how
AIM2 in£uences apoptosis, it is tempting to speculate that
interaction of AIM2 with p202 may overcome p202’s ability
to prevent apoptosis under reduced serum conditions [19].
Further work is needed to examine this possibility.
p202a (previously p202) is one of the most characterized
proteins in the family with respect to its biochemical and
cell growth regulatory functions and has a clear potential to
participate in the regulation of the cell cycle [15,20], di¡er-
entiation [21] and apoptosis [19]. p202 exerts some of its
growth-inhibitory e¡ects, in part, by binding and modulating
the activity of known growth regulatory proteins. These pro-
teins include the transcription factors (for example, E2F, AP-
1, MyoD and myogenin) and members of the ‘pocket’ family
of proteins (for example, retinoblastoma tumor suppressor
protein) [3,6]. However, it remains to be seen how AIM2
exerts its growth regulatory e¡ects.
AIM2 is a new member of the 200-gene family [6,12]. It was
identi¢ed as one of several genes not expressed in a human
tumorigenic melanoma cell line, but expressed upon introduc-
tion of normal chromosome 6, resulting in the suppression of
the malignant phenotype. Our observations described herein
that overexpression of AIM2 in murine ¢broblasts retards cell
proliferation provide support to the notion that AIM2 can
negatively regulate cell growth. Additionally, our observation
that in transfected cells AIM2 is primarily localized in the
cytoplasm and not the nucleus raises an interesting possibility
that in cytoplasm, AIM2 interacting proteins, such as p202,
may functionally interact with AIM2.
Our observations reported here will facilitate the identi¢ca-
tion of the functional role of AIM2 in cell growth regulation.
Further studies are in progress to examine the possibility if the
lack of AIM2 expression contributes to tumorigenesis.
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